How much is your DNA worth? As millions of people pay for home tests to check on ancestry or health risks, genetic data is becoming an increasingly valuable resource for drugmakers, triggering a race to create a DNA marketplace.
GlaxoSmithKline’s (GSK) decision to invest US$300 million in 23andMe and forge an exclusive drug development deal with the Silicon Valley consumer genetics company crystallizes the value locked up in genetic code.
The tie-up is the biggest yet involving home DNA testing, a market dominated by 23andMe and Ancestry.com, which charge less than US$100 for a saliva-based test, but can also gain voluntary consent from clients for their data to be used by third parties.
Illustration: Yusha
However, a number of new start-ups are beginning to offer people the chance to own their genetic information and sell it to data-hungry drug researchers.
Firms like EncrypGen, Nebula Genomics, LunaDNA and Zenome are using blockchain — the technology behind bitcoin — to secure sensitive DNA records and create a transaction ledger. The new players all have slightly different models, with most simply providing data platforms on which people are rewarded for providing data, although Nebula also plans to offer testing.
The idea of using genetic factors to hunt for better drugs has been around for more than 20 years, but it is only now becoming possible to gather a large enough sample to spot the rare variants responsible for many diseases.
The number of people who have had their DNA analyzed with the main testing companies has taken off since 2016 and now stands at about 17 million, DNAGeeks.com cofounder David Mittelman said.
By 2021, the figure could be more than 100 million, he said.
For drugmakers like GSK, which announced its 23andMe deal last week, access to this data offers a way to accelerate drug development, as finding a drug target linked to a human genetic variant doubles the chance of producing a new medicine.
The interest in home DNA tests, which can reveal genetic variants that might influence the chances of developing diseases including Alzheimer’s, is part of a wider drive by drugmakers to tap into a range of anonymized patient data.
Roche, for example, has spent US$4.3 billion this year buying out two specialists in cancer data, Foundation Medicine and Flatiron Health.
The trend has raised worries among campaigners about data security and privacy.
In a bid to alleviate concerns, Ancestry.com, 23andMe and other consumer genetic testing companies have now set out a “best practices” framework to ensure express consent, strong security and transparency on data use.
University of Queensland research fellow Caitlin Curtis said he estimates that 23andMe has made about US$130 million selling access to about 1 million genotypes prior to the GSK deal, implying an average price of about US$130.
23andMe chief executive Anne Wojcicki said she believes that her clients simply want to help find new treatments for intractable conditions, such as Parkinson’s disease — the focus of the first drug research project with GSK — and her company has no plans to give clients rebates if their data are sold on.
“People who have a disease or a family member with a condition are really interested in what they can do to help come up with a solution,” she said in an interview.
A spokesman for Ancestry.com said that his group did not have any current relationships with for-profit organizations, although it is working with some academic institutions.
Ancestry.com did have a 2015 deal with US biotech company Calico, the financial terms of which were not disclosed, but that has now ended.
The ability of genetic testing companies to rake in cash twice rankles with some, including geneticist George Church — the Harvard University scientist famous for wanting to resurrect the extinct Woolly mammoth — who is one of the founders of Nebula.
Nebula aims to eliminate the personal genetics companies as intermediaries between data owners and data buyers, a notion shared by rivals such as EncrypGen chief executive David Koepsell.
“We think people are going to get savvy about how their data is being sold and they are going to want a piece of that action,” Koepsell said in an interview. “Our whole model is about creating a market. People can upload and set a price for their data, and then we will see what the market will bear.”
People selling data on EncrypGen’s system will receive DNA tokens, a cryptocurrency. Other players have different plans, with LunaDNA’s community-owned database offering shares that are to generate dividends as researchers pay to access data.
Peter Pitts, president of non-profit healthcare research group the US Center for Medicine in the Public Interest, said he agrees that handing over DNA deserves financial recompense when the benefits flow to for-profit companies.
“People need to realize that they are actually paying for companies to monetize their most personal information and they are getting nothing for it,” he said.
LunaDNA cofounder Dawn Barry, who used to work at leading gene sequencing company Illumina, said that she does not expect people to make “life-changing money” from selling DNA.
However, she added: “People feel good about the transparency and control and respect that they get by being equitable partners in discovery research.”
It will not be plain sailing for the new upstart companies.
One of the main attractions for GSK in doing a deal with 23andMe is that the Google-backed Californian company has more than 5 million clients, more than 80 percent of whom have consented to participate in research and share their data.
EncrypGen, by contrast, which launched its first storage product earlier this year, has just 1,000 profiled users, about 100 of whom have uploaded DNA data so far.
When it comes to using DNA to understand the links between genetics and disease, scale matters.
“To do the analyses that are required to understand these complex links between genetics and disease, you need massive datasets,” Curtis said. “It’s hard to know how well these kinds of start-up platforms will scale up as research projects aim for millions of participants.”
Could Asia be on the verge of a new wave of nuclear proliferation? A look back at the early history of the North Atlantic Treaty Organization (NATO), which recently celebrated its 75th anniversary, illuminates some reasons for concern in the Indo-Pacific today. US Secretary of Defense Lloyd Austin recently described NATO as “the most powerful and successful alliance in history,” but the organization’s early years were not without challenges. At its inception, the signing of the North Atlantic Treaty marked a sea change in American strategic thinking. The United States had been intent on withdrawing from Europe in the years following
My wife and I spent the week in the interior of Taiwan where Shuyuan spent her childhood. In that town there is a street that functions as an open farmer’s market. Walk along that street, as Shuyuan did yesterday, and it is next to impossible to come home empty-handed. Some mangoes that looked vaguely like others we had seen around here ended up on our table. Shuyuan told how she had bought them from a little old farmer woman from the countryside who said the mangoes were from a very old tree she had on her property. The big surprise
The issue of China’s overcapacity has drawn greater global attention recently, with US Secretary of the Treasury Janet Yellen urging Beijing to address its excess production in key industries during her visit to China last week. Meanwhile in Brussels, European Commission President Ursula von der Leyen last week said that Europe must have a tough talk with China on its perceived overcapacity and unfair trade practices. The remarks by Yellen and Von der Leyen come as China’s economy is undergoing a painful transition. Beijing is trying to steer the world’s second-largest economy out of a COVID-19 slump, the property crisis and
As former president Ma Ying-jeou (馬英九) wrapped up his visit to the People’s Republic of China, he received his share of attention. Certainly, the trip must be seen within the full context of Ma’s life, that is, his eight-year presidency, the Sunflower movement and his failed Economic Cooperation Framework Agreement, as well as his eight years as Taipei mayor with its posturing, accusations of money laundering, and ups and downs. Through all that, basic questions stand out: “What drives Ma? What is his end game?” Having observed and commented on Ma for decades, it is all ironically reminiscent of former US president Harry